Home・Akcijų sąrašas・Editas Medicine Inc

Editas Medicine Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

2.87 -1.37

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.81

Max

3.02

Pagrindiniai rodikliai
By Trading Economics
Pajamos	6.8M -18M
Pardavimai	9.1M 12M
Pelnas, tenkantis vienai akcijai	-0.15
Pelno marža	-153.322
Darbuotojai	87
EBITDA	3.9M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+171.19% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	25M 432M
Ankstesnė atidarymo kaina	4.24
Ankstesnė uždarymo kaina	2.87

Naujienos nuotaikos

By Acuity

63%

37%

279 / 340 reitingas Healthcare

Editas Medicine Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-11 19:46; UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

2026-08-10 23:26; UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

2026-08-07 23:16; UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026-08-06 23:02; UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

2026-08-05 22:02; UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

2026-07-31 19:56; UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

2026-07-30 23:51; UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

2026-07-29 23:46; UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

2026-07-28 20:07; UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

2026-07-27 17:26; UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

2026-07-24 17:46; UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

2026-07-22 19:26; UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

2026-07-21 23:11; UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Editas Medicine Inc Prognozė

Kainos tikslas

By TipRanks

171.19% į viršų

12 mėnesių prognozė

Vidutinis 8 USD 171.19%

Aukščiausias 15 USD

Žemiausias 4 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Editas Medicine Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Editas Medicine Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

279 / 340 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.